Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $33.7652W HIGH $61.14
Volume
2.68 M
Value Traded
177.52 M
Short % Float
11%
+1.08%Week
+1.18%1 Month
+4.46%3 Month
+33.32%6 Month
+105.95%5 Year
+178.61%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
14.62 B
EPS (TTM)
3.47
P/E Ratio
16.99
Ent. Value
13.24 B
Total Shares
247.78 M
Float Shares
239.91 M
Insiders
3.18%
Institutions
105.74%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
EXEL Catalyst Timeline
Dated clinical, regulatory and corporate events for Exelixis, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Exelixis, Inc.
400Total events
8Upcoming
132Tier-1 (high impact)
2017 to 2030Coverage
Upcoming catalysts 2
Event history 50
▲IP Litigation RulingCabozantinibApprovedIP / Competition
Federal Circuit affirms validity of three crystalline malate salt cabozantinib patents ('439, '440, '015)
▲IP Litigation RulingIP / Competition
Federal Circuit affirms district court judgment in Exelixis v. MSN
◆Trial InitiationZanzalintinibFiledTrial
Planned initiation of Phase 3 STELLAR-316 trial of zanzalintinib in MRD+ resected CRC
resected stage II/III colorectal cancer with molecular residual diseasesource ↗
▼Trial DiscontinuedZanzalintinibFiledTrial
Phase 3 STELLAR-303 trial discontinued due to futility
metastatic colorectal cancersource ↗
◆Oral PresentationPresentation
Fireside chat at Goldman Sachs 47th Annual Global Healthcare Conference
◆Oral PresentationCabozantinibApprovedPresentation
Rapid oral presentation of MAIN-CAV: maintenance cabozantinib and avelumab vs avelumab after first-line PBC in la/mUC
locally advanced/metastatic urothelial cancersource ↗
◆Poster PresentationCabozantinibApprovedPresentation
Poster on safety and feasibility of cabozantinib in combination with MAP in newly diagnosed high-risk osteosarcoma
newly diagnosed high-risk osteosarcomasource ↗
▼Topline ReadoutZanzalintinibFiledClinical Data
Final analysis of overall survival in the NLM subgroup from STELLAR-303
non-microsatellite instability-high metastatic colorectal cancersource ↗
◆Poster PresentationCabozantinibApprovedPresentation
Poster on updated subgroup analysis of CheckMate-9ER: cabozantinib plus nivolumab vs sunitinib in aRCC with bone metastasis
advanced renal cell carcinoma with bone metastasissource ↗
◆Oral PresentationCabozantinibApprovedPresentation
Rapid oral presentation of PEMBROCABOSARC: pembrolizumab and cabozantinib in advanced UPS
advanced undifferentiated pleomorphic sarcomasource ↗
◆Poster PresentationZanzalintinibFiledPresentation
Poster on ZAMBONI: zanzalintinib for mccRCC with bone metastases previously treated with immune checkpoint inhibitors
metastatic clear cell renal cell carcinoma with bone metastasessource ↗
◆Oral PresentationCabozantinibApprovedPresentation
Interim analysis of CaboMain: cabozantinib as maintenance therapy for pediatric solid tumors
ultra-high-risk pediatric solid tumorssource ↗
◆Poster PresentationCabozantinibApprovedPresentation
Poster on efficacy and safety of cabozantinib in advanced NET by hormone functional status: subgroup analysis of CABINET
advanced neuroendocrine tumorssource ↗
◆Poster PresentationZanzalintinibFiledPresentation
Poster on contribution of atezolizumab to zanzalintinib + atezolizumab in previously treated mCRC from STELLAR-303
metastatic colorectal cancersource ↗
▲Subgroup AnalysisCABOMETYXApprovedClinical Data
Subgroup analysis of CABOMETYX in non-functional and functional NET at ASCO 2026
neuroendocrine tumorssource ↗
◆Oral PresentationCABOMETYXApprovedPresentation
Presentation of CABINET subgroup analysis at ASCO 2026
neuroendocrine tumorssource ↗
◆Oral PresentationCabozantinibApprovedPresentation
Oral presentation of phase 2 RADICAL trial of radium-223 dichloride and cabozantinib in RCC with bone metastases
renal cell carcinoma with bone metastasessource ↗
▲Partnership / LicenseZanzalintinibFiledCorporate
Clinical development collaboration with Merck to supply KEYTRUDA QLEX for STELLAR-316
resected stage II/III colorectal cancersource ↗
◆Oral PresentationPresentation
Fireside chat at Bank of America Securities 2026 Health Care Conference
◆Oral PresentationPresentation
Fireside chat at TD Cowen's 6th Annual Oncology Innovation Summit
◆Trial InitiationZanzalintinibFiledTrial
New expansion cohort in STELLAR-002 evaluating zanzalintinib + docetaxel in CRPC
castration-resistant prostate cancersource ↗
▲Partnership / LicenseZanzalintinibFiledCorporate
Clinical development collaboration with Merck for KEYTRUDA QLEX supply in STELLAR-316
colorectal cancersource ↗
●Trial InitiationZanzalintinibFiledTrial
Initiation of Phase 2 STELLAR-201 trial of zanzalintinib in recurrent meningioma
recurrent meningiomasource ↗
●Trial InitiationZanzalintinibFiledTrial
Merck initiated Phase 3 LITESPARK-034 trial of zanzalintinib plus WELIREG in advanced RCC
advanced renal cell carcinomasource ↗
◆Topline ReadoutZanzalintinibFiledClinical Data
Final analysis of OS in NLM subgroup expected mid-2026
metastatic colorectal cancersource ↗
●NDA SubmissionZanzalintinibFiledRegulatory Filing
NDA submission for zanzalintinib in combination with atezolizumab for previously treated metastatic CRC
previously treated metastatic colorectal cancersource ↗
▲FDA Filing AcceptedZanzalintinibFiledRegulatory Filing
FDA acceptance of NDA for zanzalintinib in combination with atezolizumab
previously treated metastatic colorectal cancersource ↗
▲Topline ReadoutZanzalintinibFiledClinical Data
Positive topline results from STELLAR-303: OS benefit in ITT population
metastatic colorectal cancersource ↗
▲FDA Filing AcceptedZanzalintinibFiledRegulatory Filing
FDA accepted NDA for zanzalintinib + atezolizumab in mCRC
metastatic colorectal cancersource ↗
▲FDA Filing AcceptedZanzalintinibFiledRegulatory Filing
FDA accepted NDA for zanzalintinib in combination with atezolizumab for previously treated metastatic CRC
metastatic colorectal cancersource ↗
▲Topline ReadoutZanzalintinibFiledClinical Data
STELLAR-303 met one of dual primary endpoints: OS benefit in ITT population
metastatic colorectal cancersource ↗
◆Trial InitiationZanzalintinibFiledTrial
Second Merck-sponsored pivotal trial of zanzalintinib + belzutifan in RCC anticipated to begin
renal cell carcinomasource ↗
▲Partnership / LicenseZanzalintinibFiledCorporate
Collaboration with Natera for STELLAR-316 trial using Signatera assay
resected stage II/III colorectal cancer with MRD+source ↗
●Trial InitiationZanzalintinibFiledTrial
Merck initiated Phase 3 LITESPARK-033 trial of zanzalintinib plus WELIREG in first-line advanced RCC
advanced renal cell carcinomasource ↗
▲Full ResultsZanzalintinibFiledClinical Data
Detailed positive results from STELLAR-303 presented at ESMO 2025 and published in The Lancet
advanced colorectal cancersource ↗
▲Subgroup AnalysisCABOMETYXApprovedClinical Data
Subgroup analysis of CABINET trial presented at ESMO 2025
advanced lung and thymic neuroendocrine tumorssource ↗
▲Oral PresentationCABOMETYXApprovedPresentation
Subgroup analysis of CABINET trial presented at ESMO 2025
advanced lung and thymic neuroendocrine tumorssource ↗
▲Equity OfferingCorporate
Stock repurchase program authorized (up to $750M before Dec 31, 2026)
●Management ChangeCorporate
Appointment of Dana T. Aftab, Ph.D. as EVP, Research and Development
Past FDA Catalysts and PDUFA Decisions
How EXEL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-09-10 | Cabometyx (cabozantinib s-malate) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C59 / 100
Pipeline Score
$1.9B
Pipeline Value
$9.8B
Commercial Value
Overvalued
Valuation Signal
8
Drugs Scored
0.4x
rNPV / MCap
Top 8%
Mid Cap(rank 54 of 658)
Percentile Rank
Exelixis, Inc. carries a moderate pipeline score (59/100), with $2.2B risk-adjusted pipeline value, led by Zanzalintinib in Aggressive Variant Prostate Carcinoma (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jul 2026; product lines: last four quarters to Jul 2026 (10-K and 10-Q)) Revenue $2.4B x 4.0 = $9.8B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| CABOMETYX | $2.2B | $2.0B | +9.5% |
| COMETRIQ | $9M | $9M | +1.4% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Zanzalintinib Small moleculeNCT05425940 | Colorectal Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 1,501 | Jan 31, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every EXEL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| CABOMETYX | neuroendocrine tumors | Phase 3 | 2026-05-30 | non functional NET: hazard ratio 0.26, median PFS cabozantinib 9.4 months, median PFS placebo 3.1 months; functional NET: hazard ratio 0.4, median PFS cabozantinib 12.7 months, median PFS placebo 5.4 monthsRead More | Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Beckerle Mary CDirector | Sell | -9,812 16,079 held | $53.66 | 08/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in EXEL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| KRENSAVAGE ASSET MANAGEMENT, LLC | 7.7 % (10 %) | 20.17 M | 370.69 K | -10.83% ( -45.00 K) |
EXEL Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How EXEL ranks across every disease it competes in
Competitive Position is a premium feature
See how EXEL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialEXEL News
EXELExelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
Exelixis, Inc. will participate in fireside chats at two upcoming investor conferences in September. The company is scheduled to present at the Wells Fargo 21st Annual Healthcare Conference in Boston and the Citi 2026 Biopharma Back to School Conference in New York City. These events provide a platform for Exelixis to engage with investors and discuss its strategic initiatives.
Read more →EXELExelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
Exelixis, Inc. announced that the U.S. Court of Appeals for the Federal Circuit has upheld a significant part of a previous judgment in its favor against MSN Laboratories. This ruling affirms the validity of three patents that are crucial to Exelixis' interests in the ongoing litigation. The decision is seen as a positive development for the company.
Read more →EXEL▼ -7.9%on this news
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Exelixis, Inc. has announced its financial results for the second quarter of 2026, highlighting progress in achieving corporate objectives. The company is focused on its strategic goals and has outlined milestones in its commercial, clinical, and pipeline development. CEO Michael M. Morrissey emphasized the company's commitment to executing its business strategy.
Read more →EXELExelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
Exelixis, Inc. will release its second quarter 2026 financial results on August 5, 2026, after market close. A conference call and webcast will follow at 5:00 p.m. ET for management to discuss the results and provide a business update. Access to the event will be available online.
Read more →EXELExelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
Exelixis has provided an update regarding the Phase 3 STELLAR-303 trial, which is evaluating the efficacy of Zanzalintinib in combination with an immune checkpoint inhibitor for patients suffering from metastatic colorectal cancer. The trial aims to assess the potential benefits of this combination therapy in improving patient outcomes.
Read more →EXELExelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
Exelixis has announced results from a subgroup analysis of the Phase 3 CABINET trial, which evaluates CABOMETYX in neuroendocrine tumors. The findings were presented at ASCO 2026, highlighting the drug's potential applications. Further details about the results and implications for treatment were not provided in the announcement.
Read more →EXELExelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June 2026
Exelixis, Inc. has announced its participation in fireside chats at upcoming investor conferences in June 2026. These presentations will be accessible via their website, with replays available for 30 days. The company emphasizes its commitment to advancing cancer care through innovative treatments and a robust pipeline.
Read more →EXELExelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June
Exelixis will host fireside chats during upcoming investor conferences in June. The events aim to engage with investors and discuss the company's strategies and developments. Specific details about the conferences or topics to be covered were not provided in the announcement.
Read more →EXELExelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
Exelixis has announced its participation in ASCO 2026, where it will present ongoing studies related to various tumor types. The presentations aim to showcase the company's advancements in cancer research. Specific details about the studies or findings were not disclosed in the announcement.
Read more →EXELExelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
Exelixis has announced a clinical development collaboration with Merck for the Phase 3 STELLAR-316 pivotal trial, focusing on patients with colorectal cancer. This partnership aims to enhance treatment options and advance research in this critical area. The collaboration signifies a strategic move to leverage combined expertise in oncology.
Read more →EXELExelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May 2026
Exelixis, Inc. has announced its participation in fireside chats at upcoming investor conferences in May 2026. The presentations will be available via webcast on the company's website, with replays accessible for at least 30 days. This initiative highlights Exelixis's commitment to transparency and engagement with its investor community.
Read more →EXEL▼ -5.1%on this newsshared move
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May
Exelixis will host fireside chats during upcoming investor conferences in May. The events aim to engage with investors and provide insights into the company's strategies and developments. Specific details about the conferences and topics to be discussed were not provided in the article.
Read more →EXELExelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update
Exelixis has announced its financial results for the first quarter of 2026 along with a corporate update. However, the article lacks specific details regarding the financial performance or any significant corporate developments. The information provided is minimal and does not elaborate on the implications of these results.
Read more →EXEL▲ +5.2%on this news
Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026
Exelixis, Inc. will release its first quarter 2026 financial results on May 5, 2026, after market close. A conference call and webcast will follow at 5:00 p.m. ET to discuss the results and provide a business update. The event can be accessed via the company's website, with a replay available for one year.
Read more →EXELExelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March 2026
Exelixis, Inc. has announced its participation in fireside chats at upcoming investor conferences in March 2026. The webcasts will be available on their website, allowing investors to access the discussions and replays for 30 days. This initiative highlights Exelixis's commitment to transparency and engagement with its stakeholders.
Read more →EXELExelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
Exelixis, Inc. announced strong financial results for Q4 and FY 2025, with total revenues reaching $599 million and $2.320 billion, respectively. The cabozantinib franchise generated significant growth, particularly in renal cell carcinoma and neuroendocrine tumors. Looking ahead, Exelixis is focused on expanding its oncology portfolio, particularly with zanzalintinib, which has a pending NDA for metastatic colorectal cancer. The company anticipates a milestone-rich 2026 with key clinical trial results expected.
Read more →EXELExelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
Exelixis announced that the FDA has accepted its New Drug Application for zanzalintinib in combination with atezolizumab for treating metastatic colorectal cancer. This application is based on positive results from the phase 3 STELLAR-303 trial, which showed significant improvements in overall survival. The FDA has set a target action date of December 3, 2026, for the review.
Read more →EXELExelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
Exelixis, Inc. will announce its fourth quarter and fiscal year 2025 financial results on February 10, 2026. Following the release, a conference call and webcast will be held at 5:00 p.m. ET to discuss the results and provide a business update. The event will be accessible via the company's website.
Read more →About Exelixis, Inc.
Headquarters1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502
BIOPHARMAWATCH ELITE PLUS
Trade the next EXEL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime